Longboard Pharmaceuticals

Please note: The information displayed on this page might be outdated.
Longboard Pharmaceuticals : Focused on developing a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. The company is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Listing
Public, USA
Market Cap
<100MM
Website:
Address:
4275 Executive Square
Suite 950
La Jolla, CA 92037
United States

Company Participants at Solebury 1x1 Management Access Event 2023

  • Kevin Lind, President and CEO

Upcoming Company Event Participation

Top 10 Holders of Longboard Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Cormorant Asset Management LP 15.59 2,118,283 11.65 13F 9/30/22
HBM Partners AG (Investment Management) 13.84 1,880,000 10.34 Funds 9/30/22
T. Rowe Price Associates, Inc. (Investment Management) 11.11 1,509,775 8.30 13F 9/30/22
Millennium Management LLC 7.76 1,054,559 5.80 13F 9/30/22
Fidelity Management & Research Co. LLC 6.56 891,500 4.90 13F 9/30/22
Farallon Capital Management LLC 5.97 810,500 4.46 13F 9/30/22
The Vanguard Group, Inc. 2.26 307,248 1.69 Funds 10/31/22
Vanguard Group, Inc. (Subfiler) 2.23 302,748 1.67 13F 9/30/22
Medical Strategy GmbH 1.78 241,520 1.33 Funds 7/29/22
OrbiMed Advisors LLC 0.84 113,500 0.62 13F 9/30/22

Top 10 Holders of Longboard Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Farallon Capital Management LLC 16.76 608,205 0.00 Stakes 3/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.